Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial - (JAMA)
    Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies - (BMJ)
    Dabigatran Superior to Warfarin for Reducing Strokes, Major Bleeding Events in Patients With AF: Presented at AHA - (DGDispatch)
    Benefits of Bariatric Surgery in Adolescents Persist After 2 Years: Presented at AHA - (DGDispatch)
    Electrocardiograph Errors Frequent in Diagnosing Left Ventricular Hypertrophy: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Cardiology Other
      Tako-Tsubo Or Ampulla, Transient Apical Ballooning
      Interventions in Adult Congenital Heart Disease
      Diabetes and the Heart: Diabetes and Glycemic Control - Endocrine
      Diabetes and the Heart: Cardiometabolic Screening and Hospital Care
      Diabetes and the Heart: Diabetes and Glycemic Control - Cardiovascular

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Takotsubo Cardiomyopathy Following Radioiodine Therapy for Toxic Multinodular Goitre
        Persistent Orocutaneous and Anal Fistulae Induced by Nicorandil: A Case Report
        Multiorgan Paradoxical Embolism Consequent to Acute Pulmonary Thromboembolism with Patent Foramen Ovale: A Case Report
        A Long-Term Follow-Up of a Girl With Dilated Cardiomyopathy After Mitral Valve Replacement and Septal Anterior Ventricular Exclusion
        Cardiac Injuries in Blunt Chest Trauma

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Cardiovascular Events Reduced in Japanese JIKEI Study With Valsartan: Presented at WCC

        By Ed Susman

        BARCELONA, SPAIN -- September 5, 2006 -- Addition of the angiotensin receptor blocker (ARB) valsartan to an antihypertensive regimen markedly reduced adverse cardiovascular events in a study of Japanese patients, researchers reported here at the European Society of Cardiology World Congress of Cardiology (WCC).

        Blood pressure control was equal in both arms of the study, but the difference in outcomes was substantial and there were significant decreases in cardiovascular events with valsartan, specifically stroke, bouts of angina, heart failure, and the need for hospitalization due to cardiac events, researchers said.

        "For the first time, the clinical value of valsartan added to the benefits of blood pressure control, are extended to an Asian population," said Bjorn Dahlof, MD, associate professor of medicine, Sahlgrenska University Hospital/Ostra, University of Gothenburg, Gothenburg, Sweden. "We also believe that these results -- seen in previous studies in other populations -- reach back again to be generalizable to Western communities."

        In a presentation on September 6th, Dr. Dahlof said the results indicate that aggressive blood pressure control is important "but also which blood pressure drug is the best choice to prevent outcomes."

        Dr. Dahlof is cochair of the JIKEI Heart Study, based at Jikei University School of Medicine, Tokyo, Japan.

        The trial enrolled 3,081 patients (one third women). The subjects were assigned to receive either valsartan or placebo on top of their current antihypertensive therapy, which could not include an ARB. Dr. Dahlof said the comparator medications were mainly calcium-channel blockers, beta blockers, and angiotensin-converting enzyme (ACE) inhibitors. Both groups of patients were able to reduce their blood pressure levels to a similar extent.

        Results also showed that patients on valsartan had a 39% relative-risk reduction in the primary endpoint of the study, a composite of cardiovascular mortality and morbidity. After 48 months, 92 events had occurred among patients on valsartan as opposed to 149 events in patients not taking the drug. That difference was significant at the P = .00021 level.

        The researchers also observed a 40% reduction in new or recurrent strokes. After 48 months, 29 events had occurred among patients on valsartan as opposed to 48 events in patients not on the drug. That difference was significant at the P = .028 level.

        There was also a 46% decline in the need for hospitalization due to heart failure. After 48 months, 19 events had occurred among patients on valsartan as opposed to 36 events in patients not on the drug. That difference was significant at the P = .029 level.

        In addition, the need to be hospitalized due to angina pectoris decreased by 65%. After 48 months, 19 events had occurred among patients on valsartan as opposed to 53 events in patients not taking the drug. That difference was significant at the P = .000007 level.


        [Presentation title: Japanese Investigation of Kinetic Evaluation in Hypertensive Event Study (JIKEI Heart Study): A Morbidity-Mortality Study With valsartan in a Japanese Population With Hypertension and Other Cardiovascular Disease Manifestations.]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send